摘要
目的:评价盐酸氨溴索(商品名沐舒坦)联合黄芪注射液对慢性阻塞性肺疾病(COPD)急性发作的疗效。方法:将74例患者随机分为两组,测定基础肺功能。对照组36例给予常规治疗,治疗组38例加用盐酸氨溴索注射液和黄芪注射液。结果:治疗后两组患者的咳嗽、咳痰及喘息症状明显好转,两组间治疗有效率比较有显著性差异(P<0.05);治疗后两组肺功能及血气分析都有不同程度改善,治疗组与治疗前相比有非常显著性差异(P<0.01),两组治疗后相比有非常显著性差异(P<0.01)。结论:盐酸氨溴索联合黄芪注射液有利于慢性阻塞性肺疾病急性发作患者临床症状的控制及肺功能的改善。
Objective：To evaluate the clinical effect of mucosolvan and astragalus injection on the acute attack of COPD. Methods：74 cases were randomly grouped basis of lung function. Treatment group（ n = 38 ） was given mucosolvan injection 30 mg two times a day, astragalus injection 60 mL intravenously once a day. The control group （n = 36）was given conventional therapy. Results：There were remarkable improvements on the clinical symptoms in two groups. There was remarkable difference of the effective rate between two groups after two weeks （P 〈 0. 05 ）. After treatment , the two groups FEV1% and blood gas analysis had improvements to varying degrees, the treatment group compared with the pre -treatment difference was significant（P 〈0.01 ）. The difference between the two groups after treatment was significant （P 〈0.01 ）. Conclusion： Ambroxol （Mucosolvan） combined with astragalus injection is able to control the clinical symptoms and improve the lung function for acute attack patients with COPD.
出处
《现代临床医学》
2008年第3期179-181,共3页
Journal of Modern Clinical Medicine
